Literature DB >> 7508411

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

C Cellier1, T Sahmoud, E Froguel, A Adenis, J Belaiche, J F Bretagne, C Florent, M Bouvry, J Y Mary, R Modigliani.   

Abstract

The relationships between clinical activity, endoscopic severity, and biological parameters in Crohn's disease have not been thoroughly investigated and a link was therefore sought between these three elements. The following parameters were determined simultaneously in 121 consecutive patients with colonic or ileocolonic Crohn's disease: Crohn's disease activity index, Crohn's disease endoscopic index of severity, and serum albumin, alpha 2-globulin, alpha 1-antitrypsin, orosomucoid, C reactive protein, erythrocyte sedimentation rate, platelets, lymphocyte and polymorphonuclear cell counts, haematocrit, and faecal alpha 1-antitrypsin concentration. The distribution of these parameters was studied and transformation was used so that data matched the normal distribution closely. A weak but significant correlation (r = 0.32; p < 0.001) was found between clinical and endoscopic indices in the whole group of patients and this correlation seemed to be homogenous in various patient subgroups (clinically quiescent or active disease, pure colonic disease, untreated patients). Endoscopic or clinical indices were also found to be weakly linked with biological parameters (r < 0.50). Stepwise linear regression identified C reactive protein as predictive of the clinical index, and, successively, alpha 2-globulin, erythrocyte sedimentation rate, faecal alpha 1-antitrypsin, serum orosomucoid, and alpha 1-antitrypsin as predictive of the endoscopic index. Both predictions were poor--the biological variables accounting for only 22 and 44% respectively of the clinical and endoscopic index variations. In conclusion, Crohn's disease clinical activity seems to be virtually independent of the severity of the mucosal lesions and biological activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508411      PMCID: PMC1374499          DOI: 10.1136/gut.35.2.231

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease.

Authors:  P Gomes; C du Boulay; C L Smith; G Holdstock
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

2.  Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors: 
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

3.  [Evaluation of ulcerative colitis and Crohn's disease activity by measurement of alpha-1-antitrypsin intestinal clearance (author's transl)].

Authors:  C Florent; C L'Hirondel; C Desmazures; V Giraudeaux; J J Bernier
Journal:  Gastroenterol Clin Biol       Date:  1981-02

4.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.

Authors:  B Landi; T N Anh; A Cortot; J C Soule; E Rene; J P Gendre; P Bories; A See; E H Metman; C Florent
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

5.  [Proposal of a system of criteria for the diagnosis of cryptogenetic inflammatory enterocolitis (Crohn's disease and hemorrhagic rectocolitis). A cooperative study by the Cryptogenic Enterocolitis Study Group].

Authors:  P Bernades; P Hecketsweiler; M Benozio; L Descos; Y Geffroy; J Hemet; J Loygue; R Modigliani; F Potet; J P Weill
Journal:  Gastroenterol Clin Biol       Date:  1978-12

6.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

7.  Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases.

Authors:  W Fischbach; W Becker; J Mössner; W Koch; C Reiners
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

8.  An index of inflammatory activity in patients with Crohn's disease.

Authors:  P A van Hees; P H van Elteren; H J van Lier; J H van Tongeren
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

9.  Depth of ulceration in acute colitis: correlation with outcome and clinical and radiologic features.

Authors:  N A Buckell; G T Williams; C I Bartram; J E Lennard-Jones
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

10.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).

Authors:  W R Best; J M Becktel; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

View more
  93 in total

Review 1.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 2.  Role of endoscopy in predicting the disease course in inflammatory bowel disease.

Authors:  Matthieu Allez; Marc Lémann
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 3.  Mucosal healing in inflammatory bowel disease: where do we stand?

Authors:  Christina Ha; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2010-12

4.  Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.

Authors:  Kazunari Yamamoto; Toshimi Chiba; Takayuki Matsumoto
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

5.  Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.

Authors:  Tryggve Ljung; Sofie Lundberg; Mark Varsanyi; Catharina Johansson; Peter T Schmidt; Max Herulf; Jon O Lundberg; Per M Hellstrom
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI).

Authors:  Eyal Gal; Alex Geller; Gerald Fraser; Zohar Levi; Yaron Niv
Journal:  Dig Dis Sci       Date:  2007-11-22       Impact factor: 3.199

7.  The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Authors:  Byron P Vaughn; Sveta Shah; Adam S Cheifetz
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

8.  Calprotectin as a diagnostic tool for inflammatory bowel diseases.

Authors:  Marianthi Chatzikonstantinou; Panagiotis Konstantopoulos; Spyros Stergiopoulos; Konstantinos Kontzoglou; Christos Verikokos; Despina Perrea; Dimitris Dimitroulis
Journal:  Biomed Rep       Date:  2016-09-07

Review 9.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 10.  Are we giving biologics too much time? When should we stop treatment?

Authors:  Edouard Louis; J Belaiche; C Reenaers
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.